查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600716

糖尿病神經病變市場：依治療類型、疾病類型、通路分類 - 全球預測 2025-2030

Diabetic Neuropathy Market by Treatment Type (Drugs, Physiotherapy), Disorder Type (Autonomic Neuropathy, Focal Neuropathy, Peripheral Neuropathy), Distribution channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年糖尿病神經病變市場估值為35億美元，預計2024年將達37.2億美元，複合年成長率為6.37%，預計到2030年將達54億美元。

糖尿病神經神經病變是糖尿病常見的併發症，伴隨長期高血糖引起的神經病變，影響感覺、運動和自主神經系統。糖尿病人口的迅速增加強調了早期診斷和有效管理策略的必要性。糖尿病神經病變治療的重點是症狀管理和減緩疾病進展，並滿足醫院、專科診所和居家照護機構患者的需求。該市場的成長得益於糖尿病盛行率的上升、社會意識的提高以及治療方案的進步，包括Gabapentin和Pregabalin等藥物療法以及物理療法和新再生療法等非藥物療法。開發患者友善解決方案的機會比比皆是，包括個人化醫療方法、增強型診斷工具和用於持續監測的穿戴式技術。此外，使用人工智慧來預測疾病的發作和進展有可能徹底改變患者護理。然而，市場拓展面臨治療成本上升、現有產品療效有限、早期症狀不明確而缺乏診斷等挑戰。熟練專業人員的短缺進一步使發展中地區的病患管理變得更加複雜。創新者可以透過探索新型止痛藥、聯合治療和神經修復技術來克服這些限制。促進生物技術公司和研究機構之間的夥伴關係可以加快開發新藥並擴大治療範圍。市場的未來取決於整合醫學研究、技術和以患者為中心的護理模式的跨學科創新。實現成長需要對這些快速成長的領域進行投資，並專注於確保創新快速、安全部署的監管途徑。透過解決未滿足需求管理的技術和方面的問題，公司可以提高其市場地位，並最終改善患者治療結果和未滿足的臨床需求。競爭激烈但未來性的市場表明，長期成長有利於採取與不斷發展的醫療保健模式一致的整體、綜合方法的公司。

主要市場統計
基準年[2023] 35億美元
預測年份 [2024] 37.2億美元
預測年份 [2030] 54億美元
複合年成長率（%） 6.37%

市場動態：快速發展的糖尿病神經病變市場的關鍵市場洞察

供需的動態交互作用正在改變糖尿病神經病變市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 糖尿病神經病變盛行率上升以及有效治療方法的需求
    • 提高人們對糖尿病診斷和治療的認知
    • 政府努力控制糖尿病神經病變
  • 市場限制因素
    • 臨床試驗失敗率高，糖尿病神經病變治療費用上漲
  • 市場機會
    • 糖尿病神經病變研究領域的拓展
    • 先進藥物輸送系統的開發
  • 市場挑戰
    • 與糖尿病神經病變治療相關的併發症

波特五力：駕馭糖尿病神經病變市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解糖尿病神經病變市場的外部影響

外部宏觀環境因素在塑造糖尿病神經病變市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解糖尿病神經病變市場的競爭格局

糖尿病神經病變市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣糖尿病神經病變市場供應商的績效評估

FPNV定位矩陣是評估糖尿病神經病變市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 糖尿病神經病變的盛行率和有效治療方法的需求
      • 提高對糖尿病診斷和治療的認知
      • 政府管理糖尿病神經病變的舉措
    • 抑制因素
      • 臨床試驗失敗率高，治療費用高
    • 機會
      • 擴大糖尿病神經病變的研究領域
      • 先進藥物輸送系統的開發
    • 任務
      • 與糖尿病神經病變治療相關的併發症
  • 市場區隔分析
    • 治療類型：藥物治療廣泛使用藥物來緩解疼痛、穩定神經功能
    • 疾病類型：周邊神經病變盛行率增加有利於糖尿病神經病變
    • 通路：網路藥局的出現成為便捷的醫療藥品通路
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的糖尿病神經病變市場

  • 藥物
    • 止痛藥
      • 非類固醇消炎劑
      • 鴉片類藥物
      • 話題
    • 抗驚厥藥
      • Gabapentin
      • Pregabalin
      • 托吡酯
    • 抗憂鬱症
      • 血清素和正腎上腺素再回收抑制劑
      • SSRI
      • TCA
  • 物理治療

第7章依疾病類型分類的糖尿病神經病變市場

  • 自主神經病變
  • 局部神經病變
  • 周邊神經神經病變
  • 近端神經病變

第8章糖尿病神經病變市場：依通路

  • 診所
  • 醫院
  • 網路藥房
  • 零售藥房

第9章北美及南美糖尿病神經病變市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區糖尿病神經病變市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的糖尿病神經病變市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Neuralace Medical 完成疼痛性糖尿病神經病變標籤擴展研究 (AT-PDN) 註冊，為 FDA 批准突破性非侵入性治療糖尿病神經病變疼痛鋪平道路
    • 撥款 140 萬英鎊用於開發糖尿病周邊神經神經病變的早期檢測
    • Horizo​​n Therapeutics核准FDA 批准更新 TEPEZZA (teprotumumab-TRBW) 的適應症語言，以指定在甲狀腺眼病 (TED) 患者中的使用，無論疾病活動度或持續時間如何。
    • Praetego 獲得美國國家眼科研究所 30 萬美元資助，用於開發治療糖尿病視網膜病變的新型口服藥物
    • Abbott、 Medtronic和 Nebro 正在開發 SCS 療法來治療周邊神經病變。

糖尿病患者 對於糖尿病患者

    • NeuroMetrix 推出周邊神經神經病變測試 DPNCheck 2.0
    • Tandem Diavitis Care 完成對胰島素幫浦製造商 AMF Medical 的收購
    • 寶潔健康 (P&G Health) 與 IDF 合作解決糖尿病患者的周邊神經病變
    • Glenmark Pharma 推出治療糖尿病併發症的藥物
    • Regency Pharmaceuticals 宣布完成糖尿病周邊神經神經病變2 期試驗的入組工作，並獲得 930 萬美元的 B 輪資金籌措。
    • 醫療科技Start-UpsYostra Labs 已籌集 40 億盧比種子輪資金，用於幫助患有慢性病的患者。
    • FDA核准PENS 裝置治療糖尿病周邊神經神經病變相關疼痛
    • FDA核准Medtronic神經刺激設備治療糖尿病周邊神經病變疼痛
    • RMH 與澳洲糖尿病創新加速器中心合作
    • Withings 收購醫療設備製造商 Impet Medical

公司名單

  • Stem Cell Care India
  • NeuroMetrix, Inc.
  • Astellas Pharma Inc.
  • Abbott Laboratories
  • Novartis AG
  • AdventHealth
  • AstraZeneca PLC
  • Eli Lilly and Company
  • The Procter & Gamble Company
  • Sanofi SA
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Harmonium Pharma srl
  • Boston Scientific Corporation
  • Vertex Pharmaceuticals Incorporated
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Bauerfeind AG
  • Medtronic PLC
  • Bayer AG
  • Regenacy Pharmaceuticals, Inc.
  • Viatris Inc.
  • Alkem Labs
  • Trevena, Inc.
  • Collegium Pharmaceutical, Inc.
  • Glenmark Pharmaceuticals Limited
  • Praetego, LLC
  • Nevro Corp.
  • Boehringer Ingelheim International GmbH
  • Winsantor, Inc.
  • Daiichi Sankyo Company, Limited
  • Grunenthal GmbH
Product Code: MRR-4348D129FA14

The Diabetic Neuropathy Market was valued at USD 3.50 billion in 2023, expected to reach USD 3.72 billion in 2024, and is projected to grow at a CAGR of 6.37%, to USD 5.40 billion by 2030.

Diabetic neuropathy, a frequent complication of diabetes, involves nerve damage due to prolonged high blood glucose levels, affecting sensory, motor, and autonomic nervous systems. The burgeoning diabetic population underscores the critical need for early diagnosis and effective management strategies. Diabetic neuropathy treatments hinge on symptom management and slowing disease progression, serving patient needs across hospitals, specialty clinics, and home care settings. This market's growth is fueled by rising diabetes prevalence, heightened public awareness, and advancements in therapeutic options, including medications like gabapentin and pregabalin, and non-pharmacological treatments such as physiotherapy and emerging regenerative therapies. Opportunities abound in developing personalized medicine approaches, enhanced diagnostic tools, and patient-friendly solutions such as wearable technology for continuous monitoring. Moreover, leveraging artificial intelligence to predict disease onset and progression could revolutionize patient care. However, market expansion faces challenges, including the high cost of treatments, limited efficacy of current offerings, and under-diagnosis due to vague symptomatology at early stages. A lack of skilled professionals further complicates patient management in developing regions. Innovators can target these limitations by exploring novel analgesics, combination therapies, and neural repair techniques. Fostering partnerships between biotech firms and research institutions could expedite new drug development and expand treatment accessibility. The market's future hinges on interdisciplinary innovations that integrate medical research, technology, and patient-centered care models. Capturing growth demands investment in these burgeoning areas, with attention to regulatory pathways that ensure quick yet safe deployment of innovations. By addressing both technological and educational facets of diabetic neuropathy management, firms can enhance their market position, ultimately leading to improved patient outcomes and unmet clinical needs. The market's nature as highly competitive yet promising suggests long-term growth will favor those adopting a holistic, integrated approach in line with evolving healthcare paradigms.

KEY MARKET STATISTICS
Base Year [2023] USD 3.50 billion
Estimated Year [2024] USD 3.72 billion
Forecast Year [2030] USD 5.40 billion
CAGR (%) 6.37%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Neuropathy Market

The Diabetic Neuropathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diabetic neuropathy and the need for effective treatment methods
    • Increasing awareness pertaining to diagnosis & treatment of diabetes
    • Government initiatives for the management of diabetic neuropathy
  • Market Restraints
    • High failure rate in clinical trials and high cost of diabetic neuropathy treatment
  • Market Opportunities
    • Widening diabetic neuropathy research areas
    • Development of advanced drug delivery systems
  • Market Challenges
    • Complications associated with diabetic neuropathy treatment

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Neuropathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Neuropathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic Neuropathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Neuropathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Neuropathy Market

A detailed market share analysis in the Diabetic Neuropathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Neuropathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Neuropathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Neuropathy Market, highlighting leading vendors and their innovative profiles. These include Stem Cell Care India, NeuroMetrix, Inc., Astellas Pharma Inc., Abbott Laboratories, Novartis AG, AdventHealth, AstraZeneca PLC, Eli Lilly and Company, The Procter & Gamble Company, Sanofi S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Pfizer Inc., Harmonium Pharma s.r.l., Boston Scientific Corporation, Vertex Pharmaceuticals Incorporated, Dr. Reddy's Laboratories Ltd., Lupin Limited, Bauerfeind AG, Medtronic PLC, Bayer AG, Regenacy Pharmaceuticals, Inc., Viatris Inc., Alkem Labs, Trevena, Inc., Collegium Pharmaceutical, Inc., Glenmark Pharmaceuticals Limited, Praetego, LLC, Nevro Corp., Boehringer Ingelheim International GmbH, Winsantor, Inc., Daiichi Sankyo Company, Limited, and Grunenthal GmbH.

Market Segmentation & Coverage

This research report categorizes the Diabetic Neuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Drugs and Physiotherapy. The Drugs is further studied across Analgesics, Anticonvulsants, and Antidepressant. The Analgesics is further studied across Non-Steroidal Anti-Inflammatory Drugs, Opioids, and Topical. The Anticonvulsants is further studied across Gabapentin, Pregabalin, and Topiramate. The Antidepressant is further studied across Serotonin & Norepinephrine Reuptake Inhibitors, SSRIs, and TCAs.
  • Based on Disorder Type, market is studied across Autonomic Neuropathy, Focal Neuropathy, Peripheral Neuropathy, and Proximal Neuropathy.
  • Based on Distribution channel, market is studied across Clinics, Hospitals, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetic neuropathy and the need for effective treatment methods
      • 5.1.1.2. Increasing awareness pertaining to diagnosis & treatment of diabetes
      • 5.1.1.3. Government initiatives for the management of diabetic neuropathy
    • 5.1.2. Restraints
      • 5.1.2.1. High failure rate in clinical trials and high cost of diabetic neuropathy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Widening diabetic neuropathy research areas
      • 5.1.3.2. Development of advanced drug delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Complications associated with diabetic neuropathy treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function
    • 5.2.2. Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy
    • 5.2.3. Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic Neuropathy Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Drugs
    • 6.2.1. Analgesics
      • 6.2.1.1. Non-Steroidal Anti-Inflammatory Drugs
      • 6.2.1.2. Opioids
      • 6.2.1.3. Topical
    • 6.2.2. Anticonvulsants
      • 6.2.2.1. Gabapentin
      • 6.2.2.2. Pregabalin
      • 6.2.2.3. Topiramate
    • 6.2.3. Antidepressant
      • 6.2.3.1. Serotonin & Norepinephrine Reuptake Inhibitors
      • 6.2.3.2. SSRIs
      • 6.2.3.3. TCAs
  • 6.3. Physiotherapy

7. Diabetic Neuropathy Market, by Disorder Type

  • 7.1. Introduction
  • 7.2. Autonomic Neuropathy
  • 7.3. Focal Neuropathy
  • 7.4. Peripheral Neuropathy
  • 7.5. Proximal Neuropathy

8. Diabetic Neuropathy Market, by Distribution channel

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals
  • 8.4. Online Pharmacy
  • 8.5. Retail Pharmacy

9. Americas Diabetic Neuropathy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diabetic Neuropathy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diabetic Neuropathy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
    • 12.3.2. GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy
    • 12.3.3. Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
    • 12.3.4. Praetego awarded USD 300,000 by National Eye Institute to advance novel oral drug for diabetic retinopathy
    • 12.3.5. Abbott, Medtronic, and Nevro are developing SCS therapies to treat peripheral neuropathy treatment

a diabetic for diabetic

    • 12.3.6. NeuroMetrix launched peripheral neuropathy test DPNCheck 2.0
    • 12.3.7. Tandem Diabetes Care completed acquisition of insulin pump maker AMF Medical
    • 12.3.8. P&G Health, IDF partnered to address Peripheral Neuropathy in people with diabetes
    • 12.3.9. Glenmark Pharma launched drug for diabetic patients with comorbidities
    • 12.3.10. Regenacy Pharmaceuticals announced the completion of enrollment for phase 2 Study in diabetic peripheral neuropathy & USD 9.3 million series B financing
    • 12.3.11. Medtech startup Yostra Labs raised Rs 4Cr in a Seed round to help patients suffering from chronic disease
    • 12.3.12. FDA Clears PENS Device for pain related to diabetic peripheral neuropathy
    • 12.3.13. FDA cleared Medtronic's neurostimulator for diabetic peripheral neuropathy pain
    • 12.3.14. The RMH partnered with Australian Centre for Accelerating Diabetes Innovations
    • 12.3.15. Withings acquired Devicemaker Impeto Medical

Companies Mentioned

  • 1. Stem Cell Care India
  • 2. NeuroMetrix, Inc.
  • 3. Astellas Pharma Inc.
  • 4. Abbott Laboratories
  • 5. Novartis AG
  • 6. AdventHealth
  • 7. AstraZeneca PLC
  • 8. Eli Lilly and Company
  • 9. The Procter & Gamble Company
  • 10. Sanofi S.A.
  • 11. Merck KGaA
  • 12. Teva Pharmaceutical Industries Ltd.
  • 13. Novo Nordisk A/S
  • 14. Pfizer Inc.
  • 15. Harmonium Pharma s.r.l.
  • 16. Boston Scientific Corporation
  • 17. Vertex Pharmaceuticals Incorporated
  • 18. Dr. Reddy's Laboratories Ltd.
  • 19. Lupin Limited
  • 20. Bauerfeind AG
  • 21. Medtronic PLC
  • 22. Bayer AG
  • 23. Regenacy Pharmaceuticals, Inc.
  • 24. Viatris Inc.
  • 25. Alkem Labs
  • 26. Trevena, Inc.
  • 27. Collegium Pharmaceutical, Inc.
  • 28. Glenmark Pharmaceuticals Limited
  • 29. Praetego, LLC
  • 30. Nevro Corp.
  • 31. Boehringer Ingelheim International GmbH
  • 32. Winsantor, Inc.
  • 33. Daiichi Sankyo Company, Limited
  • 34. Grunenthal GmbH

LIST OF FIGURES

  • FIGURE 1. DIABETIC NEUROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC NEUROPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIABETIC NEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIABETIC NEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC NEUROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC NEUROPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SEROTONIN & NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SSRIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TCAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY AUTONOMIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY FOCAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PROXIMAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 327. DIABETIC NEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 328. DIABETIC NEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023